This site is intended for a US audience Non-US Residents For Patients and Caregivers

Welcome to CTEPH.com

CTEPH is life-threatening and underdiagnosed

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, life-threatening medical condition that is underdiagnosed.1,2 The most common symptoms of CTEPH include exercise intolerance, fatigue, and dyspnea. Patients may also experience chest discomfort, syncope, hemoptysis, light-headedness, or peripheral leg edema.1

Because these symptoms are nonspecific and similar to more common diseases, like asthma, chronic obstructive pulmonary disease, and other types of pulmonary hypertension (PH), CTEPH is often misdiagnosed.1,2

 

CTEPH can be cured

CTEPH can potentially be cured with pulmonary thromboendarterectomy (PTE) surgery.1 PTE is the recommended treatment for patients who are surgical candidates.1

PTE is also sometimes called pulmonary endarterectomy (PEA).

Learn more about PTE

CTEPH.com is developed by Bayer HealthCare. Bayer is committed to advancing CTEPH best practices, including working to help inform the community that3:

 

  • All persons in whom PH is suspected should receive a ventilation/perfusion scan to screen for CTEPH3

  • All persons diagnosed with CTEPH should be assessed for potentially curative PTE surgery by an expert center3

  

  

As many as 1 out of 25 pulmonary embolism (PE) patients previously treated with ≥3 months of anticoagulation therapy could develop CTEPH2,4,5*

LEARN MORE

The Basics of CTEPH

Review the essential information about CTEPH.

Compensated by Bayer for video.

*Based on a study with 223 patients in which 3.8% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism with or without prior deep-vein thrombosis (95% CI, 1.1 to 6.5). CTEPH did not develop after two years in any of the 132 remaining patients with more than 2 years of follow-up.

   

References:

1. Piazza G and Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364:351-360. 2. Tapson VF and Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3:564-567. 3. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62(suppl D):D92-D99. 4. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264. 5. Wilkens H, Lang I, Behr J, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011;154(Suppl 1):S54-S60.

BAYER and the Bayer Cross are registered trademarks of Bayer. All other trademarks are property of their respective owners. These trademark owners are not affiliated with Bayer and do not sponsor or endorse Bayer.

 

Site last modified 09/2023

© 2023 Bayer. All rights reserved.